SGLT2 inhibitor
Also written as: SGLT2 — sodium-glucose co-transporter 2 inhibitor
A class of diabetes medications that provide cardiovascular protection by reducing heart failure hospitalizations and major adverse cardiovascular events.
Full Definition
Sodium-glucose co-transporter 2 inhibitors are antidiabetic medications that block glucose reabsorption in the kidneys, leading to glucose excretion in urine. Beyond glycemic control, these agents have demonstrated significant cardiovascular benefits in clinical trials, including reduced risk of heart failure hospitalizations, cardiovascular death, and progression of kidney disease. They are increasingly used in cardiovascular prevention strategies for patients with and without diabetes.
Usage
Usage note: Often abbreviated as SGLT2i in clinical literature; ensure proper capitalization of the '2' as a subscript when possible.
In Context
- "The patient was started on an SGLT2 inhibitor for cardiovascular protection despite well-controlled diabetes." — Clinical practice guideline
- "SGLT2 inhibitors have shown consistent benefits in reducing heart failure outcomes across multiple cardiovascular outcome trials." — Medical review article